Keep a symptom diary noting pain location, severity (on a 0-10 scale), timing relative to meals and medication doses, and associated symptoms
Questions to explore: Ask Synapse Hiro LS Researcher AI may make mistakes
Switching Between Escalation or Maintenance Dosage of RYBELSUS Formulations *Discontinue this formulation and initiate the alternate formulation the day after Switching from OZEMPIC to RYBELSUS (formulation R1) or RYBELSUS (formulation R2) Switching from OZEMPIC to RYBELSUS (formulation R1) One week after discontinuing 0.5 mg of subcutaneous OZEMPIC, start 7 mg or 14 mg of RYBELSUS (formulation R1) orally once daily

Repeated the above amino acids coupling and Fmoc deprotection steps with remaining amino acids as per the amino acid sequence of Semaglutide by using Fmoc-Gly- OH, Fmoc-Arg(pbf)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala- OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala- OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu- OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc- Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)- OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH coupled to H-Arg(Pbf)-Gly-CTC Resin by linear approach to provide the title compound
Not on the back of a single blockbuster launch or one companys breakout quarter but because the entire value chain, from intermediates makers to CDMO players to branded formulations are firing on all cylinders simultaneously